The FDA approval process for a medical device depends on its risk class. Most low-risk Class I devices are exempt from premarket review; most moderate-risk Class II devices reach the market through 510(k) clearance by proving substantial equivalence to an existing device; high-risk Class III devices require Premarket Approval (PMA), a far longer process that usually demands clinical trial evidence. A 510(k) typically takes several months of FDA review, while a PMA takes years and costs orders of magnitude more. Getting the classification and pathway right at the start is the single most consequential decision in medical device development.

Step 1: Determine your device class

The FDA sorts devices into three classes by risk and by the controls needed to assure safety and effectiveness:

  • Class I — low risk: tongue depressors, manual instruments, many wellness accessories. General controls apply; most are 510(k)-exempt but still require registration, listing, and quality practices.
  • Class II — moderate risk: infusion pumps, powered wheelchairs, most diagnostic equipment and connected monitoring devices. This is where most new devices land.
  • Class III — high risk: implants and life-sustaining devices such as pacemakers and heart valves.

You find your class by locating the product classification regulation that matches your device's intended use. Intended use is decisive: the same sensor hardware can be a wellness product outside FDA device review or a Class II medical device, purely based on the claims you make. Our medical device development pillar covers how intended use shapes the whole program.

The 510(k) pathway: clearance by substantial equivalence

A 510(k) submission argues your device is substantially equivalent to a legally marketed predicate device — same intended use, and same technological characteristics or differences that raise no new safety questions. The submission bundles device description, performance testing (bench, electrical safety, biocompatibility, software documentation, sometimes animal or clinical data), labeling, and the equivalence comparison. FDA's review target is 90 days, but rounds of additional-information requests commonly stretch the calendar to six months or more. Total preparation and testing costs for a typical Class II device usually run from tens of thousands into the low hundreds of thousands of dollars — the FDA user fee itself is a minor line, with small-business discounts available. The outcome is clearance, not approval: a legal distinction worth using correctly in your marketing.

The PMA pathway: approval with clinical evidence

PMA is the FDA's most stringent review, reserved for Class III devices. Instead of comparing to a predicate, you must independently demonstrate reasonable assurance of safety and effectiveness — almost always with clinical trial data, plus full manufacturing information and facility inspections. Timelines run years from first submission, and total program costs including clinical studies routinely reach many millions of dollars. PMA products gain a powerful moat: competitors cannot ride a predicate to follow you quickly.

De Novo: the middle road for novel low-risk devices

If your device is novel — no predicate exists — but the risk profile is low or moderate, the De Novo pathway lets FDA classify it into Class I or II with appropriate special controls. A successful De Novo also makes your device the predicate for future 510(k)s, including your own next generations.

What the FDA expects behind the submission

Every pathway sits on the same foundation: design controls under the FDA's quality system regulation — documented user needs, design inputs and outputs, verification, validation, and risk management (ISO 14971), with software and cybersecurity documentation for connected devices developed under recognized standards. This is why regulated devices must be engineered for compliance from the first sketch: the design history file is built during development, not reconstructed after. Purpose-built medical device prototyping, disciplined electronics development, and documented prototype development stages generate exactly the evidence your submission needs. Devices with radios also carry standard product obligations like FCC authorization alongside FDA review — parallel tracks familiar from any new product development program.

Plan the pathway before you engineer the product

The cheapest regulatory strategy is the one chosen before the design is frozen — pathway, predicate, and testing plan decided early, so every prototype iteration produces submission-grade evidence. Projects House develops medical devices with the regulatory endgame designed in from day one, working alongside your regulatory consultants. Contact us through the form to discuss your device and its fastest sound route to market.